Ratio Therapeutics Closes $70 Million Series C Financing to Advance Clinical Development of Targeted Radiotherapeutics Pipeline and Expand Manufacturing Infrastructure

Ratio Therapeutics, Inc. has successfully closed a $70 million Series C financing round, significantly bolstering its financial resources to advance its clinical programs and manufacturing capabilities. The financing, announced on July 31, 2026, included participation from both existing investors, such as Duquesne Family Office and Bristol Myers Squibb, and new investors including Catalio Capital Management, Eli Lilly and Company, and Wasatch Group. This latest round brings Ratio's total capital raised to over $240 million, positioning the company for its next phase of growth in the competitive oncology sector.

Ratio Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative radiopharmaceuticals for cancer treatment. Its lead asset, [Ac-225]RTX-2358, is currently undergoing evaluation in the ATLAS Phase 1/2 trial, specifically targeting advanced sarcomas. The newly raised funds will primarily support the ongoing ATLAS study and facilitate the transition of additional radioligand therapy candidates into clinical trials. Furthermore, Ratio aims to expand its discovery pipeline to include new oncology targets, addressing significant unmet medical needs and tapping into substantial market opportunities.

The strategic rationale behind this financing is underscored by the growing demand for advanced cancer therapies. Radiopharmaceuticals represent a promising frontier in oncology, offering targeted treatment options that can improve patient outcomes. Ratio's commitment to enhancing its proprietary radiopharmaceutical technology and scaling its manufacturing capabilities is critical to meeting future demand as the company prepares for increased clinical activity and potential commercialization of its therapies.

The participation of notable investors in this round reflects a strong confidence in Ratio's innovative approach and operational execution. The company has demonstrated significant progress in clinical milestones, strategic partnerships, and the establishment of a robust manufacturing infrastructure. These factors are essential in a sector where the ability to deliver effective therapies efficiently can distinguish leading firms from their competitors.

Looking ahead, the successful completion of this financing round positions Ratio Therapeutics to capitalize on the growing interest in radiopharmaceuticals and the broader oncology market. As the company advances its clinical studies and expands its pipeline, it will likely play a pivotal role in shaping the future of cancer treatment. The ongoing investment in radiopharmaceutical innovation not only highlights the potential for improved patient outcomes but also reflects the increasing importance of targeted therapies in the evolving landscape of oncology.